Lilly and Oura link wearable data to obesity treatment

Eli Lilly's direct-to-consumer telehealth platform, LillyDirect, has partnered with wearable maker Oura to combine sleep and activity tracking with obesity drug treatment. Under the deal, LillyDirect customers can now get a free sizing kit for the Oura Ring, a device that tracks sleep, activity, and other biometric signals.^[1]

The companies say the partnership responds to how patients already use Oura. More than half of Oura's user base considers itself overweight or obese, and tens of thousands of users already log their use of GLP-1 receptor agonist drugs inside the Oura app, according to the company.^[1]

Oura's chief medical officer, Ricky Bloomfield, said the goal is to connect daily habits with real-time biometric data to support "lasting results — not just in weight on the scale, but in how people feel and function every day."^[1] LillyDirect's US senior vice president, Jannifer Mazur, framed the move as part of a shift in how obesity care is delivered, saying the focus is moving beyond the moment a prescription is written to the "daily moments that shape long-term success."^[1]

This is not Oura's first move into obesity care. The company previously launched a feature called GLP-1 Insights, designed to give patients a data-based view of their progress while on GLP-1 drugs.^[1] Oura has also linked its ring with Dexcom's over-the-counter continuous glucose monitor, Stelo, letting non-diabetic users track blood glucose alongside sleep and activity data.^[1]

Why it matters for patients

For patients using incretin drugs like semaglutide or tirzepatide through LillyDirect, this partnership means an optional path to add wearable tracking to their treatment, at no extra cost for the ring sizing kit.^[1] The stated aim is to give patients and possibly their care teams more visibility into sleep and activity patterns alongside drug treatment, rather than relying on periodic weigh-ins or lab visits alone.^[1]

The move reflects a broader industry trend described in the source: obesity treatment is shifting from a drug-only model toward what companies call a wider care ecosystem, blending behavioral tools, wearables, and medication.^[1] Voy chief medical officer Earim Chaudry, speaking at the 2026 HLTH Europe conference, put it directly: medications are "the start, not the destination."^[1] Lilly has also worked with the UK government to expand access to digital platforms and community-based obesity support, suggesting the company sees data and services as central to its obesity strategy beyond the US.^[1]

The source does not specify what LillyDirect or a patient's clinician actually does with the sleep and activity data once collected, whether it affects prescribing decisions, or whether use of the Oura Ring is required or simply offered as an option. It also does not address cost to patients beyond the free sizing kit, data privacy terms, or how this integration differs from Oura's existing GLP-1 Insights feature. Those details are not yet known from the available reporting.

What happens next

The source does not give a specific rollout date for when LillyDirect customers can begin requesting sizing kits, nor does it describe next steps such as clinical evaluation of the combined approach. Broader context suggests this fits into an industry-wide trend, highlighted at the 2026 HLTH Europe conference in Amsterdam, of pairing wearables and digital tools with obesity drugs, following Oura's earlier integration with Dexcom's Stelo glucose monitor.^[1]